Pancreatic Cancer
Conditions
Brief summary
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
Detailed description
This is a multicenter, open-label, single-arm, phase Ib/II clinical study to evaluate the safety, tolerability, and antitumor activities of IN10018 + standard chemotherapy (albumin paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. This study includes two cohorts, Cohort 1: IN10018 + standard chemotherapy; Cohort 2: IN10018 + standard chemotherapy + KN046. Each cohort consists of 2 phases: a dose confirmation phase and a dose expansion phase. The dose confirmation phase aims to determine recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer. According to the Package Insert of standard chemotherapy (albumin paclitaxel and gemcitabine), the Investigator's Brochure (IB) and drug characteristics of KN046, it is expected that IN10018 has little possibility of interaction with standard chemotherapy and KN046, and the safety characteristics are clearly non-overlapping. The therapeutic dose of KN046, albumin-bound paclitaxel and gemcitabine are fixed in this study. In the dose confirmation phase, IN10018 dose will be modified according to the causality between dose-limiting toxicities (DLTs) and IN10018.
Interventions
DRUGIN10018
IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
DRUGAlbumin-Bound Paclitaxel
Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
DRUGGemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.
DRUGKN046
KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
Sponsors
InxMed (Shanghai) Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. With a full understanding of the study, each subject voluntarily agreed to participate in this study and sign the informed consent form. 2. Female or male subjects ≥ 18 years at the time of signing informed consent. 3. Histological or cytology-confirmed pancreatic ductal adenocarcinoma (including adenosquamous carcinoma). 4. No previous systemic treatment for unresectable, locally advanced, or metastatic pancreatic cancer. 5. At least one measurable lesion per RECIST 1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Life expectancy of at least 3 months as assessed by the investigator. 8. Must have recovered from all AEs due to previous anticancer therapies to ≤ Grade 1 (CTCAE 5.0) or stable status as assessed by the investigator. Subjects with any grade of alopecia and grade 2 peripheral neuropathy could be enrolled. 9. Adequate bone marrow, liver, renal, and coagulation function . 10. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: * Not a woman of childbearing potential (WOCBP) . or * A WOCBP who agrees to follow the contraceptive guidance.
Exclusion criteria
1. Has had major surgery or major trauma within 28 days prior to the first dose of study treatment. 2. Has known BRCA1/2 mutations. 3. Has received prior systemic anticancer therapy including chemotherapy, targeted therapy, immunotherapy, unmarketed investigational drugs or therapy within 28 days prior to the first dose of study treatment. 4. Previous anti-programmed death 1(PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody therapy, or any other antibody or drug that specifically targets T-cell co-stimulation or checkpoint pathways, or prior treatment with focal adhesion kinase (FAK) inhibitors. 5. Has received radical radiotherapy within 3 months prior to the first dose of study treatment. Subjects who have received palliative radiotherapy with a local standardized dose within 2 weeks prior to the first dose of study treatment. 6. Has received previous allogeneic hematopoietic stem cell transplantation or organ transplantation. 7. Has received live vaccines and live attenuated vaccines within 28 days prior to the first dose of study treatment. 8. Has interstitial pneumonia or lung disease. 9. History or current active autoimmune diseases. 10. Has a prior history of other malignancy, other than cured cutaneous squamous cell carcinoma, basal cell cancer, non-basal invasive bladder cancer, and prostate/cervical/breast cancer in situ within 5 years prior to the first dose of study treatment. 11. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 12. Has a history of major cardiovascular, cerebrovascular or thromboembolic diseases within 6 months before the first dose of study treatment. 13. Active infection with poor systemic treatment control. 14. Has known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or hepatitis C (HCV) infection, or active syphilis and tuberculosis. 15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Related Adverse Events （AEs） | 1 year | Incidence and severity of AEs, with severity determined according to the NationalCancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) |
| To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer. | 2 years | Proportion of subjects who have the best objective response of either complete response (CR) or partial response (PR), as assessed by the investigator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) per RECIST 1.1, as evaluated by investigators | 1 years | Defined as the time from the first day of study treatment to the first disease progression or death due to any cause, whichever occurs first. |
| Disease Control Rate (DCR) per RECIST 1.1, as evaluated by investigators | 1 year | Proportion of subjects who have CR, PR, or stable disease (SD). |
| Incidence of Treatment-Related AEs | 2 years | Incidence and severity of AEs, with severity determined according to the NCI CTCAE v5.0 |
| Overall survival (OS) | 2 years | Defined as the time from the first day of study treatment to death due to any cause. |
| duration of response (DoR) per RECIST 1.1, as evaluated by investigators | 1 years | Available for subjects who demonstrate CR or PR, DoR is defined as the time from the first evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first, as assessed by the investigator. |
Countries
China
Contacts
Primary ContactBohong Zhang
Outcome results
None listed